Evidence map›Paper›PMID 37326746›Full record

ReviewMolecular biology reports2023

A review of basic to clinical targeted therapy and immunotherapy in uterine serous cancer.

Bowen Sun, Na Zhao, Yuan Cheng, Jianliu Wang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular biology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Role of signaling pathways in endometrial cancer.Molecular biology reports · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Bowen Sun *Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, China.
Na Zhao *Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, China.
Yuan ChengDepartment of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, China. chengyuan@bjmu.edu.cn.ORCID http://orcid.org/0000-0002-4476-7241
Jianliu WangDepartment of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, 100044, China. wangjianliu@pkuph.edu.cn.
Peking University · CN

Funding

Fund for Fostering Young Scholars of Peking University Health Science Center BMU2022PY002National Natural Science Foundation of China 81802607National Natural Science Foundation of China 81874108National Natural Science Foundation of China 82173119
6 · The paper itself

Abstract

Uterine serous carcinomas show more frequent mutations of TP53, FBXW7, PIK3CA, and PP2R1A. Furthermore, cyclin-dependent kinase, human epidermal growth factor receptor 2, phosphatidylinositol 3-kinase/protein kinase B, and mammalian target of rapamycin signaling pathways are involved in uterine serous carcinoma progression. However, most patients with uterine serous carcinoma develop chemoresistance to paclitaxel and carboplatin. Moreover, uterine serous carcinoma shows immunosuppressive microenvironment with lower frequency of microsatellite instability. However, some clinical trials of human epidermal growth factor receptor 2/neu and WEE1 targeted therapies showed good effects in prolonging the survival in patients with uterine serous carcinoma. More effective targeted therapies and immunotherapies need to be developed in recurrent uterine serous carcinomas.

Indexed as

Cystadenocarcinoma, SerousUterine NeoplasmsCarboplatinFemaleHumansImmunotherapyPaclitaxelTumor MicroenvironmentCarboplatinPaclitaxelImmunotherapyMicrosatellite instabilityTargeted therapyUterine serous cancer

Identifiers

PMID37326746
OpenAlexW4380869999

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.